Conrad Prebys Foundation fellows Archives - Sanford Burnham Prebys
Institute News

The Conrad Prebys Foundation fellows take center stage

AuthorGreg Calhoun
Date

May 20, 2024

Following a year of hands-on training and scientific inquiry supported by a generous grant from the Conrad Prebys Foundation, a diverse group of early-career researchers recently presented their promising progress on translational research projects.

Twelve scientists-in-training at Sanford Burnham Prebys presented research updates at the Conrad Prebys Foundation Fellows Symposium on May 14, 2024, at the Institute’s Fishman Auditorium.

The presentations were the culmination of a yearlong educational program at Sanford Burnham Prebys providing early-career scientists with workshops, mentorship and research experiences focused on how to transform research discoveries into new treatments. The Conrad Prebys Foundation provided critical funding for the program as part of the foundation’s mission to increase the diversity of San Diego’s biomedical workforce.

Conrad Prebys Foundation fellows poster presentations“This truly has been a pioneering program at the Institute,” says Alessandra Sacco, PhD, director of, and professor in, the Development, Aging and Regeneration Program at Sanford Burnham Prebys; and dean of the Institute’s Graduate School of Biomedical Sciences.

The graduate students and postdoctoral fellows selected to participate in the program conducted projects at the Institute’s  Conrad Prebys Center for Chemical Genomics (Prebys Center), the nation’s leading nonprofit drug discovery center. The Prebys Center specializes in finding new medicines for diseases with a substantial unmet medical need.

“Each participant worked with a pair of co-mentors, one in the laboratory and another in the Prebys Center,” adds Sacco. In addition to extensive mentorship, the program included educational sessions about the drug discovery process.

“This program’s multifaceted approach to training and development has been incredibly rewarding,” says Sacco. Before introducing the symposium’s first speaker, Sacco thanked Michael Jackson, PhD, senior vice president of Drug Discovery and Development at the Prebys Center and director of the Institute’s Cancer Molecular Therapeutics Program; Jessica Colomb, associate director of Administration at the Prebys Center; and all the mentors who contributed to the program’s success.

Conrad Prebys Foundation fellows poster presentationsAfter the conclusion of the fellows’ formal presentations, Lauren Mitchell, MS, program manager for Diversity, Equity, Inclusion and Belonging (DEIB) at Sanford Burnham Prebys, moderated a discussion for fellowship awardees regarding how this training program enriched their skillset, benefited their career development and contributed to their overall sense of belonging and community, among other topics.

The symposium ended with a poster session and reception celebrating the Conrad Prebys Foundation, participants, mentors and contributors.

“I would like to express my utmost gratitude to the Conrad Prebys Foundation for this fellowship,” says Xiuqing Wei, PhD, postdoctoral associate in the lab of Lorenzo Puri, MD, director of, and professor in, the Development, Aging and Regeneration Program at Sanford Burnham Prebys.

Wei adds, “It was a wonderful experience working with my co-mentors on an amazing translational research project.” Wei focused on methods for targeting the abnormal regulation of a key proinflammatory cytokine which is associated with muscle waste under the conditions of nerve injuries and cancer.

The Conrad Prebys Foundation fellows who presented at the symposium were:

Postdoctoral Fellows

  • Merve Demir
    Zhao Lab, Ed Sergienko co-mentor
    “Structural studies of MtCK and GCDH enzyme drug targets”
  • Alicia Llorente Lope
    Emerling Lab, Ian Pass co-mentor
    “Exploring PI5P4Kγ as a novel molecular vulnerability of therapy-resistant breast cancer” 
  • Van Giau Vo
    Huang Lab, TC Chung co-mentor
    “Identifying enhancers of SNX27 to promote neuroprotective pathways in Alzheimer’s disease and Down Syndrome”
  • Xiuqing Wei
    Puri Lab, Anne Bang co-mentor
    “Selective targeting of a pathogenetic IL6-STAT3 feedforward loop activated during denervation and cancer cachexia”

Predoctoral Fellows

  • Michael Alexander Alcaraz
    Adams Lab, Steven Olson co-mentor
    “Activating the NAMPT-NAD+ axis in senescence to target age-associated disease”
  •   Shea Grenier Davis
    Commisso Lab, Steven Olson co-mentor
    “Examining PIKfyve as a potential therapeutic target in pancreatic cancer” 
  • Aditi Pedgaonkar
    Deshpande Lab, Ed Sergienko co-mentor
    “SGF29 as a novel therapeutic target in AML” 
  • Patrick Hagan
    Cosford Lab, Ian Pass co-mentor
    “Discovery and development of novel ATG13 degrading compounds that inhibit autophagy and treat non-small-cell lung cancer” 
  • Texia Loh
    Wang Lab, Ed Sergienko co-mentor
    “Investigating the role of HELLS in mediating resistance to PARP Inhibition in small-cell lung cancer” 
  • Michaela Lynott
    Colas Lab, TC Chung co-mentor
    “Identification of small molecules inhibiting ATF7IP-SETDB1 interacting complex to improve cardiac reprogramming efficiency” 
  • Tatiana Moreno
    Kumsta Lab, Anne Bang co-mentor
    “Identifying TFEB/HLH-30 regulators to modulate autophagy in age-related diseases” 
  • Utkarsha Paithane
    Bagchi Lab, TC Chung co-mentor
    “Identification of small-molecule enhancers of Honeybadger, a novel RAS/MAPK inhibitor”
Institute News

Opinion: Including researchers of diverse backgrounds makes science more accurate and applicable

AuthorAlessandra Sacco, Michael Jackson and Svasti Haricharan
Date

June 14, 2023

America has always been an experiment, an ongoing enterprise to determine how and how well people of different races, cultures and experiences might govern and live together. It’s an experiment that extends to every aspect of our lives. We celebrate our diversity and inclusivity through the food we eat, the languages we speak and the stories we tell.

Unfortunately, universities and other research institutions in the United States often do not have stories to tell about diversity and inclusion. People of color and women who aspire to careers in academic research are frequently discouraged early on from entering the grueling pipeline (which may extend more than a decade) by the lack of opportunities, access and accommodation.

It is no accident that non-White and female scientists are significantly and consistently underrepresented in the ranks of U.S. academic faculty: approximately 30 percent are female, just 6 percent are Black or Hispanic. Despite recent social awareness and movements toward change, the composition of tenure-track or tenured underrepresented faculty of color in the U.S. increased by only 1 percentage point (11 percent to 12 percent) between 2013 and 2019.

There are fundamental reasons why well-intentioned platitudes and policies regarding science and education don’t reflect reality. Neil A. Lewis Jr., a communications professor at Cornell University, wrote in a 2022 essay in Nature Human Behavior that “What counts as ‘good science’ tends to be research approaches that prioritize the experiences of dominant groups, and not approaches developed to prioritize people placed on the margins of society.”

He added, “The topics that count are ones that fit with the ‘master narratives’ in the field, and not the ‘counter narratives’ that sometimes emerge from marginalized groups.”

Many studies have demonstrated that the more diverse a research team is, the more likely its findings are to move fields forward and create new technologies and inventions. Simultaneously, research conducted by scientists who do not belong to dominant groups is more likely to be ignored by the larger research community, resulting in the so-called “diversity-innovation paradox” that slows scientific progress.

Historically, scientific and clinical studies have addressed research and health questions primarily through the prism of White males, overlooking or ignoring potential — or even likely differences — that might be found in women or people of color. As late as 1977, for example, the Food and Drug Administration recommended excluding women of childbearing potential from phase 1 and early phase 2 drug trials.

This is changing. It’s now well-documented that males and females differ in their response to drug treatment. Likewise, among different ethnicities. Inclusion is now law, and new research points to improved representation among communities of color in most clinical trials.

The embrace of science, technology, engineering and mathematics, or STEM, in public education has become a fundamental force for long-term good. The more children of every size, shape and color who are exposed to these disciplines, the more diverse and energized future generations of scientists, engineers and health professionals will be.

However, we are still in the first steps toward making this journey more accessible to marginalized groups. There is no mainstream movement yet in this direction. The ability to break into the upper echelons of academia continues to be constrained not only by race and ethnicity, but by privilege, with first-generation students facing many more barriers than those with at least one parent with a higher education degree. Scientists who are from the LGBTQ community also face significant challenges to finding acceptance for their research and their identity in academia.

A new educational program at Sanford Burnham Prebys, an independent biomedical research institute in La Jolla, attempts to remedy this singular reality. Funded by a grant from The Conrad Prebys Foundation, the institute has welcomed a group of 13 graduate students and postdoctoral fellows from diverse backgrounds and identities, all of whom will be working in labs, gaining hands-on experience in drug discovery and translational medicine from industry-trained researchers.

They come from near and far, having previously studied at places like San Diego State University, University of San Diego, University of Barcelona and Hong Kong University of Science and Technology. Their research interests are diverse: new treatments for breast and pancreatic cancers, how DNA repairs itself, regenerating heart muscle and how the brain protects itself from Alzheimer’s disease.

The goal is to provide these young scientists with advanced research training that will better position them to not just have successful, productive careers, but also become role models and leaders in biomedical research.

The Prebys Foundation fellows, as they are called, represent a small step in the right direction. Similar efforts are needed elsewhere, everywhere, at small and large institutions, laboratories and places where the work of science gets done.

As a nation, we must be committed to planting the seeds of new generations of scientists through programs like STEM. And when they begin to mature, we must provide the water and nutrients to ensure our young scientists bear fruit for a very long time.

Alessandra Sacco, PhD, is vice dean and associate dean of student affairs in the Graduate School of Biomedical Sciences at Sanford Burnham Prebys, and co-director of the fellowship program. Michael Jackson, PhD, is senior vice president for drug discovery and development and co-director in the Conrad Prebys Center for Chemical Genomics, and co-director of the fellowship program. Svasti Haricharan, PhD, is associate director for training and education in the NCI-Designated Cancer Center at Sanford Burnham Prebys. All live in San Diego.

This story originally appeared in San Diego Union-Tribune.

Institute News

Presenting The Conrad Prebys Foundation fellows

AuthorMiles Martin
Date

May 15, 2023

Thanks to a generous grant from The Conrad Prebys Foundation, a diverse group of early-career researchers will gain hands-on experience in drug discovery and translational medicine.

A new educational program at Sanford Burnham Prebys has welcomed a diverse group of early-career scientists to learn how to transform research discoveries into treatments for human diseases. The program was made possible by a generous grant from The Conrad Prebys Foundation as part of its mission to increase the diversity of San Diego’s biomedical workforce.

“Our mission at The Conrad Prebys Foundation is to create an inclusive, equitable and dynamic future for all San Diegans,” says Grant Oliphant, CEO at The Conrad Prebys Foundation. “San Diego is one of the top areas in the country for biomedical research, and we’re pleased to partner with Sanford Burnham Prebys to help strengthen the pipeline of diverse talent in life sciences research.”

Graduate students and postdoctoral fellows selected for the program will complete projects at the Institute’s Conrad Prebys Center for Chemical Genomics (Prebys Center), the nation’s leading nonprofit drug discovery center. The Prebys Center specializes in finding new medicines for diseases with a substantial unmet medical need in order to develop better therapies. 

“Thank you to The Conrad Prebys Foundation. I am beyond grateful for their support,” says predoctoral Prebys fellow Michael Alcaraz, who will complete his project on the links between aging and brain disease with Professor Peter D. Adams, PhD, and Steven Olson, PhD, executive director of Medicinal Chemistry at the Prebys Center. 

To help fulfill the Foundation’s mission, Sanford Burnham Prebys students and postdocs from historically underrepresented groups were encouraged to apply for the new program.

“Promoting diversity in the biomedical workforce is a founding principle of our educational program,” says Alessandra Sacco, PhD, vice dean and associate dean of Student Affairs in the Graduate School of Biomedical Sciences at Sanford Burnham Prebys. Sacco will oversee the new program alongside Dean Guy Salvesen, PhD, and Professor Michael Jackson, PhD

“Working actively to train people from all backgrounds gives opportunities to people who may not otherwise have had them—and it also improves the quality of the research itself,” she adds.

“Translational research is one of the biggest priorities in biomedicine right now because it’s how we turn discoveries into actual medicines,” says Sacco. “This program gives students and postdocs an opportunity to build the skills they need for translational research jobs in academia or industry.”

The fellowship will culminate in a final symposium next spring, where the fellows will present their research to their peers and to the wider community. 

“I’m looking forward to gaining more experience and making my contribution to the translational science at the Prebys Center,” says predoctoral Prebys fellow Merve Demir, who will complete a structural biochemistry project with Assistant Professor Jianhua Zhao, PhD, and Eduard Sergienko, PhD, director of Assay Development at the Prebys Center. 

The full list of fellows includes:
 

Postdoctoral Fellows

– Karina Barbosa Guerra [Deshpande Lab, Ed Sergienko co-mentor]
“SGF29 as a novel therapeutic target in AML”
 
– Merve Demir [Zhao Lab, Ed Sergienko co-mentor]
“Structural studies of MtCK and GCDH enzyme drug targets”
 
– Jerry Tyler DeWitt [Haricharan Lab, TC Chung co-mentor]
“Investigating the unique molecular landscape of ER+ breast cancer in black women” 
 
– Alicia Llorente Lope [Emerling Lab, Ian Pass co-mentor]
“Exploring PI5P4Kγ as a novel molecular vulnerability of therapy-resistant breast cancer” 
 
– Van Giau Vo [Huang Lab, TC Chung co-mentor]
“Identifying enhancers of SNX27 to promote neuroprotective pathways in Alzheimer’s disease and Down Syndrome”
 
– Xiuqing Wei [Puri Lab, Anne Bang co-mentor]
“Selective targeting of a pathogenetic IL6-STAT3 feedforward loop activated during denervation and cancer cachexia”

 

Predoctoral Fellows

– Michael Alexander Alcaraz [Adams Lab, Steven Olson co-mentor]
“Activating the NAMPT-NAD+ axis in senescence to target age-associated disease”
 
– Shea Grenier Davis [Commisso Lab, Steven Olson co-mentor]
“Examining PIKfyve as a potential therapeutic target in pancreatic cancer” 
 
– Patrick Hagan [Cosford Lab, Ian Pass co-mentor]
“Discovery and development of novel ATG13 degrading compounds that inhibit autophagy and treat non-small-cell lung cancer”
 
– Texia Loh [Wang Lab, Ed Sergienko co-mentor]
“Investigating the role of HELLS in mediating resistance to PARP Inhibition in small-cell lung cancer”
 
– Michaela Lynott [Colas Lab, TC Chung co-mentor]
“Identification of small molecules inhibiting ATF7IP-SETDB1 interacting complex to improve cardiac reprogramming efficiency”
 
– Tatiana Moreno [Kumsta Lab, Anne Bang co-mentor]
“Identifying TFEB/HLH-30 regulators to modulate autophagy in age-related diseases”
 
– Utkarsha Paithane [Bagchi Lab, TC Chung co-mentor]
“Identification of small-molecule enhancers of Honeybadger, a novel RAS/MAPK inhibitor”